Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030794 (pelvic pain)
 4,056 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The origins of benign prostatic diseases, such as benign prostatic hyperplasia (BPH) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), are poorly understood. Patients suffering from benign prostatic symptoms report a substantially reduced quality of life, and the relationship between benign prostate conditions and prostate cancer is uncertain. Epidemiologic data for BPH and CP/CPPS are limited, however an apparent association between BPH symptoms and cardiovascular disease (CVD) has been consistently reported. The prostate synthesizes and stores large amounts of cholesterol and prostate tissues may be particularly sensitive to perturbations in cholesterol metabolism. Hypercholesterolemia, a major risk factor for CVD, is also a risk factor for BPH. Animal model and clinical trial findings suggest that agents that inhibit cholesterol absorption from the intestine, such as the class of compounds known as polyene macrolides, can reduce prostate gland size and improve lower urinary tract symptoms (LUTS). Observational studies indicate that cholesterol-lowering drugs reduce the risk of aggressive prostate cancer, while prostate cancer cell growth and survival pathways depend in part on cholesterol-sensitive biochemical mechanisms. Here we review the evidence that cholesterol metabolism plays a role in the incidence of benign prostate disease and we highlight possible therapeutic approaches based on this concept.
 ...
PMID:Cholesterol and benign prostate disease. 2186 1

The article presents the results of neurophysiological examination of 32 patients with noninflammatory form of abacterial chronic prostatitis/ chronic pelvic pain syndrome (CP/CPPS III B). Intramuscular electromyography was performed, right and left bulbocavernous reflex and cortical somatosensory evoked potentials during stimulation of n. pudendus were evaluated. It is shown that there is a high frequency of abnormal neurophysiological patterns in the absence of clinical neurological disease in patients with CP/CPPS III B. In this case, the pain as the main symptom was not associated with prostate disease. It is suggested that some patients with a diagnosis of CP/CPPS III B have neurological pathology that not manifested at the time of the examination.
 ...
PMID:[Neurophysiologic evaluation of patients with chronic prostatitis (III B chronic pain syndrome)]. 2311 21